TLR4 and cancer: Moreover, because of its ability to activate TLR4, FNIII EDA has been explored in cancer vaccinology, utilizing FNIII EDA-antigen fusion proteins as DC-targeting adjuvants to induce anti-tumor CTLs28, 30, 31.